BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1617677)

  • 1. Subcellular distribution of the anticancer drug mitoxantrone in human and drug-resistant murine cells analyzed by flow cytometry and confocal microscopy and its relationship to the induction of DNA damage.
    Smith PJ; Sykes HR; Fox ME; Furlong IJ
    Cancer Res; 1992 Jul; 52(14):4000-8. PubMed ID: 1617677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flow cytometric analysis and confocal imaging of anticancer alkylaminoanthraquinones and their N-oxides in intact human cells using 647-nm krypton laser excitation.
    Smith PJ; Desnoyers R; Blunt N; Giles Y; Patterson LH; Watson JV
    Cytometry; 1997 Jan; 27(1):43-53. PubMed ID: 9000584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line.
    Hazlehurst LA; Foley NE; Gleason-Guzman MC; Hacker MP; Cress AE; Greenberger LW; De Jong MC; Dalton WS
    Cancer Res; 1999 Mar; 59(5):1021-8. PubMed ID: 10070958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
    Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
    Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells.
    Kamath N; Grabowski D; Ford J; Drake F; Kerrigan D; Pommier Y; Ganapathi R
    Cancer Commun; 1991 Feb; 3(2):37-44. PubMed ID: 1995027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.
    Cole SP; Chanda ER; Dicke FP; Gerlach JH; Mirski SE
    Cancer Res; 1991 Jul; 51(13):3345-52. PubMed ID: 1675932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
    Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
    Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
    Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
    Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
    Chen S; Gomez SP; McCarley D; Mainwaring MG
    Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
    Wolverton JS; Danks MK; Schmidt CA; Beck WT
    Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan.
    Danks MK; Garrett KE; Marion RC; Whipple DO
    Cancer Res; 1996 Apr; 56(7):1664-73. PubMed ID: 8603418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II.
    Potmesil M; Hsiang YH; Liu LF; Bank B; Grossberg H; Kirschenbaum S; Forlenza TJ; Penziner A; Kanganis D
    Cancer Res; 1988 Jun; 48(12):3537-43. PubMed ID: 2836060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
    Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM
    Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy.
    Gervasoni JE; Fields SZ; Krishna S; Baker MA; Rosado M; Thuraisamy K; Hindenburg AA; Taub RN
    Cancer Res; 1991 Sep; 51(18):4955-63. PubMed ID: 1680024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
    Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of apoptosis in neoplastic cells by anthracycline antitumor drugs: nuclear and cytoplasmic triggering?
    Serafino A; Sinibaldi-Vallebona P; Pierimarchi P; Bernard P; Gaudiano G; Massa C; Rasi G; Ranagnan G
    Anticancer Res; 1999; 19(3A):1909-18. PubMed ID: 10470135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines.
    Vibet S; Mahéo K; Goré J; Dubois P; Bougnoux P; Chourpa I
    Drug Metab Dispos; 2007 May; 35(5):822-8. PubMed ID: 17296624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone.
    Fox ME; Smith PJ
    Cancer Res; 1990 Sep; 50(18):5813-8. PubMed ID: 2168281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells.
    Hazlehurst LA; Argilagos RF; Emmons M; Boulware D; Beam CA; Sullivan DM; Dalton WS
    Cancer Res; 2006 Feb; 66(4):2338-45. PubMed ID: 16489039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.